Cited by 140Fatty Acid Research and HealthInflammatory mediators and NSAID effectsEicosanoids and Hypertension Pharmacology

Identification and structure elucidation of the pro‐resolving mediators provides novel leads for resolution pharmacology

Open access
Dalli, Jesmond, Serhan, Charles N·2019·British Journal of Pharmacology

Abstract

Inflammatory diseases are a major socio‐economic burden, with the incidence of such conditions on the rise, especially in western societies. For decades, the primary treatment paradigm for many of these conditions was to develop drugs that inhibit or antagonize the production and biological actions of molecules that were thought to be the culprits in propagating disease; these include cytokines and eicosanoids. This approach is effective in controlling disease propagation; however, long‐term exposure to these anti‐inflammatories is also associated with many side effects, some of which are severe, including immune‐suppression. The discovery that termination of self‐limited acute inflammation is an active process orchestrated by endogenous mediators, including the essential fatty acid‐derived resolvins, protectins and maresins, has provided novel opportunities for the design of therapeutics that control inflammation with a lower burden of side effects. This is because at variance to anti‐inflammatories, pro‐resolving mediators do not completely inhibit inflammatory responses; instead, these mediators reprogramme the immune response to accelerate the termination of inflammation, facilitating the regain of function. The scope of this review is to highlight the biological actions of these autacoids and their potential utility as lead compounds in developing resolution pharmacology‐based therapeutics. Linked Articles: This article is part of a themed section on Eicosanoids 35 years from the 1982 Nobel: where are we now? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.8/issuetoc

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bph.14336

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SPMs suppress inflammation but, unlike anti-inflammatory drugs, promote both repair and continued pathogen clearance.

    “From a translational perspective, SPMs suppress inflammation but, unlike anti-inflammatory drugs, these pro-resolving mediators promote both repair and continued pathogen clearance33,213–215.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

2 of the 106 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Malagoli D (2016). The Evolution of the Immune System: Conservation and Diversification, Elsevier: London, UK.

Cited by

Sorted by citations

Authors
Dalli, J., & Serhan, C. N.
Affiliations
  • Queen Mary University of London (GB)
  • Brigham and Women's Hospital (US)
Corresponding author
Dalli, Jesmond
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2018-06-03
Volume
176
Issue
8
Pages
1024-1037
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2801066468
Cited by
138
References
106
Citations by year
2026: 11 · 2025: 14 · 2024: 7 · 2023: 16 · 2022: 23 · 2021: 20 · 2020: 27 · 2019: 15 · 2018: 5
FWCI
2.18
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Queen Mary Research Online (Queen Mary University of London) (submittedVersion, cc-by)
Funders
  • H2020 European Research Council (677542)
  • National Institutes of Health (P01GM095467, R01GM38765)
  • Wellcome Trust (107613/Z/15/Z)
  • Royal Society
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Pharmacology › Inflammatory mediators and NSAID effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
Keywords
specialized pro-resolving mediators, resolvins, protectins, maresins, eicosanoids, essential fatty acids, immune reprogramming, autacoids, inflammatory diseases, lead compounds
MeSH terms
Drug Development, Animals, Anti-Inflammatory Agents, Humans, Eicosanoids, Inflammation Mediators, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review